Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Frontiers in OncologyOpen Access

Immunotherapy resistance in triple-negative breast cancer: Molecular mechanisms, tumor microenvironment, and therapeutic implications

View Full Paper
Ask AI
Bookmark
Share

Authors

ZZZijian ZhouQZQin Zhou

Discussion

Loading...

Member takes

Overview

This review explores immunotherapy resistance in triple-negative breast cancer, highlighting molecular mechanisms and tumor microenvironment interactions.

Key Points

  • Immunotherapy resistance presents significant challenges in treatment for triple-negative breast cancer (TNBC), impacting patient outcomes.
  • The review identifies complex molecular mechanisms and signaling pathways contributing to resistance, with implications for therapy.
  • Immunotherapy demonstrates promise in overcoming previous assumptions about breast cancer's insensitivity, particularly in TNBC.
  • The tumor microenvironment, characterized by immune cells and PD-L1 expression, plays a crucial role in resistance and treatment strategies.

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/68c24317b210217d647a5f2chttps://doi.org/10.3389/fonc.2025.1630464
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation2025 · 5 citations
  2. 2Improving efficacy of TNBC immunotherapy: based on analysis and subtyping of immune microenvironment2024 · 12 citations
  3. 3The Evolving Landscape of Immunotherapy in Triple-negative Breast Cancer: Mechanisms, Biomarkers, and Future Horizons2025
  4. 4Inflammation-associated drug resistance and tumor growth in TNBC2025 · 10 citations
  5. 5Chemotherapeutics as Immune Modulators for the Treatment of Triple-Negative Breast Cancer2026